EUCTR2010-023957-12-SE进行中（未招募）不适用
Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradiotherapy and surgery - RAPIDO
Dutch Colorectal Cancer Group0 个研究点目标入组 885 人开始时间: 2011年2月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 885
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Biopsy-proven, newly diagnosed primary rectal adenocarcinoma, i.e. with the lowest part of the tumour less than 16 cm from the anal verge using a rigid rectoscope or flexible endoscope .
- •Locally advanced tumour fulfilling at least one of the following criteria on pelvic MRI indicating high risk of failing locally and/or systemically:
- •oClinical stage (c) T4a, i.e. overgrowth to an adjacent organ or structure like the prostate, urinary bladder, uterus, sacrum, pelvic floor or side-wall (according to TNM version 5).
- •ocT4b, i.e. peritoneal involvement.
- •oExtramural vascular invasion (EMVI+).
- •oN2, i.e. four or more lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease. Four or more nodes, whether enlarged or not, with a rounded, homogeneous appearance is thus not sufficient.
- •oPositive MRF, i.e. tumor or lymph node one mm or less from the mesorectal fascia.
- •oEnlarged lateral nodes, > 1 cm (lat LN+).
- •Staging done within 5 weeks before randomization.
- •No contraindications to chemotherapy, including adequate blood counts:
- •- white blood count ?4.0 x 109/L
- •- platelet count ?100 x 109/L
- •- clinically acceptable haemoglobin levels
- •- creatinine levels indicating renal clearance of ?50 ml/min
- •- bilirubin ?35 µmol/l.
- •ECOG performance score ? 1, see appendix B.
- •Patient is considered to be mentally and physically fit for chemotherapy as judged by the oncologist.
- •Age ? 18 years
- •Written informed consent.
- •Adequate potential for follow-up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen.
- •Presence of metastatic disease or recurrent rectal tumour. Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn’s disease or active ulcerative Colitis.
- •Concomitant malignancies, except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years.
- •Known DPD deficiency.
- •Any contraindications to MRI (e.g. patients with pacemakers).
- •Medical or psychiatric conditions that compromise the patient’s ability to give informed consent.
- •Concurrent uncontrolled medical conditions.
- •Any investigational treatment for rectal cancer within the past month.
- •Pregnancy or breast feeding.
- •Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract.
- •Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the past 12 months.
- •Patients with symptoms or history of peripheral neuropathy.
研究者
相似试验
进行中（未招募）
不适用
Rectal cancer And Pre-operative Induction therapy followed by DedicatedOperatioEUCTR2010-023957-12-ESniversity Medical Center Groningen (UMCG)885
进行中（未招募）
不适用
Rectal cancer And Pre-operative Induction therapy followed by Dedicated OperatioEUCTR2010-023957-12-SIInstitute of Oncology Ljubljana885
进行中（未招募）
不适用
Rectal cancer And Pre-operative Induction therapy followed by DedicatedOperatioEUCTR2010-023957-12-DKniversity Medical Center Groningen (UMCG)885
已完成
3 期
Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradiotherapy and surgery and optional adjuvant chemotherapy (RAPIDO study)rectal cancer10017990NL-OMON47895niversitair Medisch Centrum Groningen361
进行中（未招募）
1 期
Study to investigate a short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery compared to standard chemoradiotherapy and surgery in in rectal cancerEUCTR2010-023957-12-NLMC Groningen920